Evaluation of the Performance of the Doraldo-Castelletti Scale in Supporting the Neurologist's Decision to Refer Migraine Patients to Physiotherapy

ConditionMigraine
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorIstituto Auxologico Italiano

About this trial

Migraine is the leading cause of disability worldwide among people aged 15 to 49. Although therapies targeting the CGRP pathway have improved the management of the condition, there are large groups of patients who do not respond to medications or for whom these are contraindicated. In this context, non-pharmacological therapies such as physical therapy play a crucial role.

The scientific literature highlights a strong link between migraine and cervical disorders:

* 77% of migraine patients suffer from neck pain. * 93% have at least three musculoskeletal dysfunctions in the cervical region. * Patients with cervical symptoms experience more frequent attacks, greater disability, a poorer response to medication, and a higher risk of chronicity.

Despite the proven utility of physical therapy for the prevention and treatment of migraine (as demonstrated by validated physical tests and standardized questionnaires such as the NDI, HDI, and HIT-6), musculoskeletal screening is not routinely included in neurological examinations. Neurologists in headache centers generally lack the time and specific manual skills required to perform a thorough physical assessment of the cervical spine.

There is therefore a lack of a rapid and effective screening tool that serves as a "bridge" between neurology and rehabilitation.

The primary objective of the MIGSKA study is to evaluate the performance of the Doraldo-Castelletti scale in assessing the clinical need and motivation of patients with migraine to undergo physical therapy. The study will also assess the utility of this scale as a decision-making tool for neurologists in referring appropriate patients to physical therapists.

To address this gap in clinical practice, the study analyzes the Doraldo-Castelletti scale. The adoption of this tool aims to:

* Easily identify migraine patients with significant musculoskeletal dysfunction. * Quantify the patient's attitude and motivation toward manual therapy (a determining factor for treatment success). * Provide the neurologist with an objective and rapid criterion for prescribing a specialized physical therapy evaluation, promoting a genuine and effective multidisciplinary approach to migraine care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 70 years (inclusive)

Diagnosis of migraine established by a neurologist specialized in headache disorders

Headache Impact Test (HIT-6) ≥ 42

Ability to understand the study informed consent

Disqualifiers

Neurological diseases confounding the primary objective

Conditions confounding the primary objective (e.g., fibromyalgia, which could limit patient evaluation by the physiotherapist)

Previous physiotherapy treatments specifically for headache management

Psychiatric disorders confounding and/or interfering with the primary objective

Trial design

Design model

Single group

Treatments tested in this trial

  • Doraldo-Castelletti scale

    Other intervention

    During a routine neurological examination, the physician administers the Doraldo-Castelletti scale to the migraine patient. The scale consists of 10 multiple choice questions.

Treatment groups

439 Participants
are divided into 1 treatment group
Group A: Doraldo Castelletti scaleExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Score of the Doraldo-Castelletti scale

Scale consisting of 10 multiple choice questions; Minimum score = 0; Maximum score = 13

Time frame
At baseline
2

Proportion of patients referred to physiotherapist

Proportion of patients referred to physiotherapist on the basis of the score of the Doraldo-Castelletti scale

Time frame
At baseline

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.